Alam Kamran 4

What Happened

• Alam Kamran, Chief Financial Officer of Taysha Gene Therapies (TSHA), disposed of 1,655 shares on Feb 4, 2026. The shares were reported sold at $4.52 per share for a total proceeds of $7,481. This was a sale (not a purchase) and is reported as an open market/private sale.

Key Details

• Transaction date and price: Feb 4, 2026 — 1,655 shares at $4.52 each.
• Proceeds: $7,481.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The sale was made under a mandatory sell-to-cover arrangement to satisfy income tax liabilities from the vesting of restricted stock units (RSUs). (Footnote F1)
• Filing timeliness: Reported on Feb 6, 2026 — filed two days after the transaction (timely for Form 4).

Context

• This sale was a tax-withholding sell-to-cover tied to RSU vesting, a routine administrative transaction that doesn't necessarily reflect the insider's view of the company's outlook. Purchases by insiders tend to be more informative about confidence; tax-related disposals are common and often required by company plans.